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Sir, 
We thank Meffert and co-workers [1] for their interest in our study and for providing data 
which support our finding of an association between carriage of rs738409:G in PNPLA3 and 
the risk of liver-associated mortality, at least in men. [2]  The authors evaluated the 
association of rs738409:G with mortality in adults participating in a population-based health 
study in Pomerania.  The included population of 4081 was sub-classified by sex and by the 
absence/presence of hepatic steatosis on ultrasound.  Participants were censored at death 
or when lost to follow-up with the length of follow-up defined as birth to censorship.  The 
median follow-up period was 11.3 (interquartile range: 10.6-11.8) years, though this is 
difficult to equate with the definition of the follow-up period provided.  In men carriage of 
the rs738409:G was associated with a fourfold increase in the hazard ratio for liver-disease-
related mortality; there were too few events in women for analysis.  These data 
corroborates not only our findings that carriage of rs738409:G is a negative risk factor for 
survival [2] but also the reported association with a reduction in survival in people listed for 
liver transplantation [3] and in those with cirrhosis and hepatocellular carcinoma [4].  The 
authors also showed that, in men, carriage of rs738409:G was associated with a decrease in 
the risk of death from coronary artery disease; there was no such effect in women [1].  Lui 
and colleagues [5] recently reported in an exome-wide association study in >300,000 
individuals that carriage of rs738409:G was associated with a lower risk of coronary artery 
disease so corroborating this finding although sex-specific data were not provided.   
 
The main point of interest in the data provided by Meffert and co-workers [1] is the 
apparent sex-related differences in disease-specific mortality associated with carriage of 
rs738409:G, which needs to be confirmed.  Consequently we re-analysed our study data to 
test for the presence of interactions between sex and the rs738409:G allele and medium-
term mortality (90 to 450 days after initial presentation).  The study populations and data 
processing methodology were as described in the original publication of these data [2, 6].  
Information on deaths within the study period was collected via the study reporting forms 
while information on deaths out with the study period were obtained from the NHS 
Information Centre Data Linkage service.  Tests for allelic association were performed using 
logistic regression analysis with introduction of a multiplicative interaction term for 
rs738409 genotype and sex.  Cox regression analysis was used to examine for associations 
between survival, rs738409:G, sex and a return to drinking with incorporation of a 
multiplicative interaction term for rs738409:G and sex. 
 
Eight-two (20.7%) of the 397 patients included in the analysis died during the follow-up 
period  Information on the cause of death was only available in 60 (73%); the deaths in 47 
(78%) were classified as definitely liver-related; two were definitely not liver-related whilst 
the remaining 11 deaths were not classifiable as such.  There was a highly significant 
multiplicative interaction between rs738409 genotype and sex in relation to medium-term 
mortality (hazard ratio [HR] 0.30, 95% CI 0.14 – 0.62, P=0.001) which was independent of 
the return to drinking (HR 2.91, 95% CI 1.88 – 4.50, P<0.001).  Of particular note was the 
sex-specific difference in the survival in homozygous carriers of rs738409:G; thus all eight 
female homozygotes survived to day 450 compared with only ten (48%) of their 21 male 
counterparts (Figure 1).  
 
The comparative survival advantage in women with alcohol-related cirrhosis is well-
documented [7-10].  Nevertheless, its occurrence is unexplained, although differences in 
body composition which result in relative preservation of lean muscle mass in women may 
play a significant role. [11,12]  However, the findings reported by Meffert et al, [1] and 
confirmed in the reanalysis of our study data suggest that the sex-related differences in the 
risk of liver-related deaths may relate to sex-variant interaction with rs738409:G in PNPLA3.  
Sex-variant interactions have previously been described in the field of cardiovascular 
medicine [13] and are worthy of further exploration in the field of liver medicine.  
 
Figure 1 
Medium-term survival in cases with severe alcoholic hepatitis surviving at least 90 days, by gender and 
drinking status. (A) In male patients who maintain abstinence rs738409:G is associated with an apparent 
reduction in survival over the 90-450 day period. (B) The same pattern is seen in male patients who return to 
drinking. In female patients the pattern appears to be reversed (C and D). 
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